Butyrophilin subfamily 3 member A1–phosphoantigen complex (BTN3A1/pAg complex)

Molecular Classification

Receptor (immunoglobulin superfamily, structurally related to B7 family), Immune modulator, Phosphoantigen sensor

Other Names

BTN3A1, CD277, Butyrophilin subfamily 3 member A1, Butyrophilin 3A1, BTN3.1

Disease Roles

Cancer (tumor surveillance and immune therapy)Infection (response to infected cells)Inflammation (immunomodulation)

Butyrophilin subfamily 3 member A1–phosphoantigen complex Overview

Butyrophilin subfamily 3 member A1 (BTN3A1) is a type I transmembrane receptor in the immunoglobulin superfamily, closely related to the B7 family. It contains extracellular Ig-like domains and a unique intracellular B30.2 (PRYSPRY) domain, which binds small pyrophosphate-containing phosphoantigens (such as HMBPP and IPP). In complex with these phosphoantigens, BTN3A1 undergoes a conformational change, enabling the formation of a heterodimer with BTN2A1. This complex is recognized by the Vγ9Vδ2 T cell receptor, fundamentally activating this major subset of human γδ T cells, which execute immune responses against tumor cells and pathogens through cytotoxicity and cytokine secretion[1][2][3][4][5][9]. BTN3A1 is essential for the sensing of metabolic changes unique to transformed or infected cells and is a promising immunotherapeutic target[2][9]. No direct small-molecule antagonists or inhibitors of BTN3A1 are in routine clinical use, but therapeutics may act by modulating phosphoantigen levels or antibody-based agonism.

Mechanism of Action

Agonistic antibodies: trigger conformational changes in BTN3A1, mimicking phosphoantigen binding and activating Vγ9Vδ2 T cells; Phosphoantigen accumulation: increases activation of Vγ9Vδ2 T cells by engaging BTN3A1; Small molecule modulation: altering endogenous levels of phosphoantigens (IPP, HMBPP)

Biological Functions

Immune response (innate and adaptive)

T-cell activation (especially Vγ9Vδ2 γδ T cells)

Regulation of T cell proliferation and cytokine release

Immunosurveillance (anti-tumor, anti-infection)

Disease Associations

Cancer (tumor surveillance and immune therapy)

Infection (response to infected cells)

Inflammation (immunomodulation)

Safety Considerations

Over-activation may cause excessive immune responses (cytokine release syndrome)
Potential for autoimmunity if non-specific T cell activation is triggered

Interacting Drugs

Indirectly targeted by drugs that modulate phosphoantigen levels, such as nitrogen-containing bisphosphonates (e.g., zoledronate), which cause accumulation of phosphoantigens like IPP

Emerging bispecific antibodies and agonistic antibodies targeting BTN3A1

Associated Biomarkers

Biomarker
BTN3A1 expression levels in tumors or blood cells for immune therapy biomarkers
Vγ9Vδ2 T cell activation as a readout of BTN3A1 engagement